GLOBUS MEDICAL INC (GMED): Results of Operations and Financial Condition
GLOBUS MEDICAL INC (GMED) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gmed-q22026ex991.htm EX-99.1 Document Exhibit 99.1 Globus Medical Reports Second Quarter 2026 Results AUDUBON, PA., August 6, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quar
How this was made
The 30-second read
Why it matters
The key tradable inputs are the raised full-year non-GAAP EPS range and the Q2 non-GAAP EPS surge, supported by commentary on adjusted gross margin expansion and operating leverage.
Market read
GMED’s guidance update (non-GAAP EPS raised) and Q2 non-GAAP profitability improvement are fresh catalysts that can drive near-term positioning and options implied moves.
What to watch
Traders may discount non-GAAP strength if they expect normalization of adjusted items or if revenue growth is concentrated in specific product lines (US Spine and International Spine) rather than broad-based durability.
Background
This is an SEC 8-K with Exhibit 99.1 reporting Globus Medical’s Q2 2026 financial results and full-year 2026 guidance update, plus conference call details.
Ticker impact
Globus Medical reported Q2 2026 results and updated full-year guidance, including raising non-GAAP EPS to $4.95-$5.05.
Likely positive bias for the next session as traders weigh raised non-GAAP EPS guidance versus GAAP EPS distortion from the prior-year Nevro bargain purchase gain.
The filing provides fresh, decision-relevant numbers: Q2 non-GAAP diluted EPS up 55.8% and full-year non-GAAP EPS range raised to $4.95-$5.05, alongside revenue growth and margin expansion commentary.
Market effects
Musculoskeletal/spine medtech peers may see read-across on demand and margin trajectory if GMED’s growth and adjusted profitability are sustained.
International revenue growth (up 18% as-reported) highlights continued ex-US momentum that could influence regional medtech sentiment.
Limited direct global macro linkage, but guidance revisions can affect broader risk appetite in medtech earnings season.
Counterpoint
GAAP EPS fell 26.2% due to the prior-year Nevro bargain purchase gain, so headline EPS comparisons may overstate underlying operating momentum.
Key entities
- companyGlobus Medical, Inc.
Subject of the filing, reporting Q2 2026 results and updating full-year 2026 guidance.
- executiveKeith Pfeil
CEO quoted on revenue growth drivers and the company’s ecosystem strategy.
- executiveKyle Kline
CFO quoted on margin expansion, operating leverage, and synergy realization.
